This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chow EJ, Mueller BA, Baker KS, Cushing-Haugen KL, Flowers ME, Martin PJ et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med 2011; 155: 21–32.
Armenian SH, Sun CL, Vase T, Ness KK, Blum E, Francisco L et al. Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood 2012; 120: 4505–4512.
Annaloro C, Usardi P, Airaghi L, Giunta V, Forti S, Orsatti A et al. Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 797–804.
Majhail NS, Flowers ME, Ness KK, Jagasia M, Carpenter PA, Arora M et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2009; 43: 49–54.
Bassi N, Karagodin I, Wang S, Vassallo P, Priyanath A, Massaro E et al. Lifestyle modification for metabolic syndrome: a systematic review. Am J Med 2014; 127: e1–e10.
Demark-Wahnefried W, Jones LW . Promoting a healthy lifestyle among cancer survivors. Hematol Oncol Clin North Am 2008; 22: 319–342.
Vale MJ, Jelinek MV, Best JD, Dart AM, Grigg LE, Hare DL et al. Coaching patients On Achieving Cardiovascular Health (COACH): a multicenter randomized trial in patients with coronary heart disease. Arch Intern Med 2003; 163: 2775–2783.
Jelinek M, Vale MJ, Liew D, Grigg L, Dart A, Hare DL et al. The COACH program produces sustained improvements in cardiovascular risk factors and adherence to recommended medications-two years follow-up. Heart Lung Circ 2009; 18: 388–392.
World Health Organization Physical status: the use and interpretation of anthropometry. World Health Organization: Geneva, 1995.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et alHarmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation 2009; 120: 1640–1645.
Cameron AJ, Magliano DJ, Zimmet PZ, Welborn T, Shaw JE . The metabolic syndrome in Australia: prevalence using four definitions. Diabetes Res Clin Pract 2007; 77: 471–478.
Natarajan P, Ray KK, Cannon CP . High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 2010; 55: 1283–1299.
Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8–15.
Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410–418.
Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011; 34: 1481–1486.
Acknowledgements
We acknowledge the participants of the study as well as the staff of the Late Effects Clinic at The Alfred Hospital, particularly Helen McLauchlan. This project was supported by the Victorian Government.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Viner Smith, E., Tierney, A., Klarica, D. et al. Impact of a lifestyle modification program on the metabolic syndrome and associated risk factors in long-term survivors of stem cell transplantation. Bone Marrow Transplant 51, 722–724 (2016). https://doi.org/10.1038/bmt.2015.312
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.312
This article is cited by
-
Cell Therapy for Ischemic Stroke: How to Turn a Promising Preclinical Research into a Successful Clinical Story
Stem Cell Reviews and Reports (2019)
-
Type 2 Diabetes Mellitus, the Metabolic Syndrome, and Its Components in Adult Survivors of Acute Lymphoblastic Leukemia and Hematopoietic Stem Cell Transplantations
Current Diabetes Reports (2018)